Biggest News Aggregation in the World
📰 Nasdaq Elev News

Page 2 - Nasdaq Elev News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Nasdaq Elev. Real-time updates on events, politics, business and more.

Elevation Oncology (NASDAQ:ELEV) Lifted to Outperform at SVB Securities

SVB Securities upgraded shares of Elevation Oncology (NASDAQ:ELEV – Get Rating) from a market perform rating to an outperform rating in a report released on Tuesday morning, The Fly reports. They currently have $8.00 price objective on the stock, up from their previous price objective of $5.00. Separately, Wedbush reaffirmed an outperform rating and issued […]
United States Geode Capital Management Sio Capital Management Renaissance Technologies Tang Capital Management Elevation Oncology Inc

Elevation Oncology, Inc. (NASDAQ:ELEV) Sees Large Decline in Short Interest

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 369,100 shares, a decline of 64.2% from the April 30th total of 1,030,000 shares. Based on an average daily trading volume, of 822,600 shares, the days-to-cover ratio […]
United States Elevation Oncology Company Profile Sio Capital Management Renaissance Technologies Geode Capital Management Tang Capital Management
Source: wkrb13.com

Elevation Oncology (NASDAQ:ELEV) & Freeline Therapeutics (NASDAQ:FRLN) Head-To-Head Contrast

Elevation Oncology (NASDAQ:ELEV – Get Rating) and Freeline Therapeutics (NASDAQ:FRLN – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk. Institutional & Insider Ownership 68.0% of Elevation Oncology shares […]
United States United Kingdom New York Freeline Therapeutics Holdings Elevation Oncology Inc Elevation Oncology

Equities Analysts Issue Forecasts for Elevation Oncology, Inc.'s Q2 2023 Earnings (NASDAQ:ELEV)

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) – Investment analysts at Wedbush lifted their Q2 2023 earnings per share estimates for Elevation Oncology in a research note issued on Monday, May 15th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.25) per share for the quarter, up from their prior estimate of […]
United States Sio Capital Management Elevation Oncology Company Profile Geode Capital Management Elevation Oncology Inc Virtu Financial
Source: wkrb13.com

Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Up 688.7% in April

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) was the recipient of a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 688.7% from the April 15th total of 130,600 shares. Based on an average daily trading volume, of 766,300 shares, […]
United States Elevation Oncology Inc Elevation Oncology Company Profile Tang Capital Management Annandale Capital Blackrock Inc

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Update

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 688.7% from the April 15th total of 130,600 shares. Based on an average daily volume of 766,300 shares, the short-interest ratio is presently 1.3 days. […]
United States Renaissance Technologies Elevation Oncology Inc Capital Management Millennium Management Annandale Capital
Source: wkrb13.com

Elevation Oncology, Inc. (NASDAQ:ELEV) Short Interest Update

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 123,200 shares, an increase of 135.6% from the March 15th total of 52,300 shares. Approximately 0.8% of the shares of the company are sold short. Based on […]
United States Elevation Oncology Company Profile Virtu Financial Capital Management Elevation Oncology Inc Annandale Capital
Source: wkrb13.com

Elevation Oncology (ELEV) and Its Rivals Head to Head Survey

Elevation Oncology (NASDAQ:ELEV – Get Rating) is one of 255 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Elevation Oncology to similar companies based on the strength of its profitability, valuation, risk, earnings, dividends, institutional ownership and analyst recommendations. Insider & […]
New York United States Elevation Oncology Company Profile Get Rating Elevation Oncology Inc Elevation Oncology Get Rating

Analysts Set Elevation Oncology, Inc. (NASDAQ:ELEV) Target Price at $17.82

Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) has earned a consensus rating of “Buy” from the six analysts that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among […]
United States Northern Trust Corp Elevation Oncology Company Profile Get Rating Goldman Sachs Group Inc Zacks Investment Research America Corp

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science